Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures

Abstract

Overview

Late Onset Alzheimer's Disease is the most prevalent form of dementia, associated with amyloid-β (Aβ) peptide plaques and hyperphosphorylated tau protein tangles. This study explores a non-invasive method using repeated electromagnetic field stimulation (REMFS) to reduce Aβ levels.

Findings

• Effects of REMFS were tested at various frequencies, powers, and specific absorption rates (SAR) on primary human brain (PHB) cultures over different intervals.
• Treatment at 64 MHz for 1-hour daily over 14 days significantly decreased Aβ40 and Aβ42 peptide levels without inducing cellular toxicity.
• A minimum of 0.4 W/kg SAR was essential for observable biological effects.
• No significant alteration in secreted amyloid precursor protein-alpha (sAPPα) levels, suggesting the reduction in Aβ was not due to redirection towards the α-secretase pathway.

Conclusion

The frequencies and powers of EMF utilized in this study are comparable to those used in MRI, indicating the potential for clinical applications of REMFS in managing Alzheimer's Disease by modulating Aβ deposition.